Healthcare Industry News: Solvay Pharmaceuticals
News Release - August 22, 2006
Omeros Names Greg Perkins, Ph.D., as Vice President, Regulatory AffairsSEATTLE--(HSMN NewsFeed)--Aug. 22, 2006--Omeros Corp., a Seattle-based biopharmaceutical company, has hired J. Greg Perkins, Ph.D., as Vice President, Regulatory Affairs. Dr. Perkins will oversee all regulatory, compliance and QA/QC areas for the growing company.
"Dr. Perkins has over 20 drug approvals to his credit," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, "and is well versed in all phases of drug development. His experience and knowledge will be invaluable in helping us achieve our commercialization goals for the products in our pipeline."
With over 30 years in the pharmaceutical industry, Perkins has been a senior executive at Solvay Pharmaceuticals, Hoffman-LaRoche, and Burroughs Wellcome. His most recent position at Solvay Pharmaceuticals was Senior Vice President, Global Scientific Affairs and Milestone Review, where he elucidated the mechanism of action for Estraest, a widely prescribed female hormone replacement product. In his 10 years at Solvay he supervised clinical/scientific data and programs for numerous drugs including Luvox, where he obtained approval for the drug and an extension of exclusivity.
His previous experience includes the position of Vice President, Drug Regulatory Affairs, for Hoffman-LaRoche Inc. There he was responsible for all regulatory affairs and was the FDA liaison for all Roche U.S. ethical drugs and helped introduce ddC for AIDS.
Prior to Hoffman-LaRoche, he worked at Burroughs Wellcome as Head of Regulatory Affairs (Consumer Products) where, during the course of his tenure, he was responsible for the design and execution of clinical trials as well as devising and executing a program for the OTC conversion of Actifed and devising regulatory strategies for the approval of AZT for AIDS.
"The combination of strong leadership at Omeros, coupled with the company's promising pipeline, affords me the perfect opportunity," said Perkins. "I look forward to being part of its dynamic environment and growth for some time to come."
Perkins is a graduate of Indiana University with a B.S. in chemistry and a Ph.D. in biochemistry. He also was a postdoctoral Fellow in neurochemistry at the University of Iowa. Perkins has written numerous NDAs, INDs and scientific papers, and is co-author of the book, "Pharmaceutical Marketing: Principles, Environment, and Practice," 2002. He was also senior editor for the "Haworth Series in Drug Discovery."
Omeros Corp. is a biopharmaceutical company advancing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. Omeros' patented product candidates are based on a systems biology approach: there is no single pathway or mediator responsible for inflammation, pain or any other problem resulting from disease or the trauma of surgery. Problems like inflammation and pain are the result of integrated and interacting networks of pathways and mechanisms. Product candidates are designed to act on multiple molecular targets at the site of delivery to improve therapeutic benefit while minimizing the risk of side effects. Omeros is located at 1420 Fifth Ave., Suite 2600, Seattle, WA 98101, Phone: 206-676-5000, Fax: 206-264-7856, www.omeros.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.